You are here:
| Reference : Treatment of drug-induced toxic epidermal necrolysis (Lyell’s syndrome) with intravenous... |
| Scientific journals : Article | |||
| Human health sciences : Dermatology Human health sciences : Anesthesia & intensive care | |||
| http://hdl.handle.net/2268/17027 | |||
| Treatment of drug-induced toxic epidermal necrolysis (Lyell’s syndrome) with intravenous human immunoglobulins | |
| English | |
Paquet, Philippe  [Université de Liège - ULg > > Dermatopathologie >] | |
| Jacob, Emilie [Université de Liège - ULg > Administration de l'enseignement et des étudiants > AEE : Cellule programmes des cours - Diplômes >] | |
| Damas, Pierre [Université de Liège - ULg > > Soins intensifs >] | |
| Pierard, Gérald [Université de Liège - ULg > > Dermatopathologie >] | |
| 2001 | |
| Burns : Journal of the International Society for Burn Injuries | |
| Elsevier | |
| 27 | |
| 6 | |
| 652-655 | |
| Yes (verified by ORBi) | |
| International | |
| 0305-4179 | |
| 1879-1409 | |
| New York | |
| NY | |
| [en] Toxic epidermal necrolysis ; Lyell’s syndrome ; Immunoglobulin ; Apoptosis | |
| [en] Toxic epidermal necrolysis (TEN) is a rare drug-induced life-threatening disease. Currently, the disease is only treated by supportive and antiseptic measures. Quite recently intravenous immunoglobulins (IG) were shown to be a promising TEN treatment. The rationale for their use is based on the fact that keratinocyte apoptosis in TEN involves the CD95 (APO-1/Fas) cell
surface receptor–ligand system. We successfully treated a TEN patient with high dose of intravenous IG. The clinical recovery appeared exceptionally rapid. Immunohistochemistry showed that the IG action probably developed on the CD95 receptor–ligand system at the keratinocytes surface. | |
| Researchers ; Professionals | |
| http://hdl.handle.net/2268/17027 |
| File(s) associated to this reference | ||||||||||||||
|
Fulltext file(s):
| ||||||||||||||
All documents in ORBi are protected by a user license.
